RemeGen Co

RemeGen Co EBIT per Share

The EBIT per Share of RemeGen Co (688331.SS) as of Oct 27, 2026 is 1.32 CNY. In the previous year, EBIT per Share was -2.71 CNY — a change of -148.54% (higher).

EBIT per Share

1.32CNY

YoY

-148.54%

Last updated:

EBIT per Share of RemeGen Co is 2025 1.32 CNY. EBIT per Share of RemeGen Co was 2024 -2.71 CNY. It decreases by -148.54% higher compared to the previous year.

The RemeGen Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-2.78 CNY
Jan 1, 2024
-2.71 CNY
Jan 1, 2025
1.32 CNY
Jan 1, 2027 (e)
1.70 CNY
Jan 1, 2028 (e)
3.26 CNY
Jan 1, 2029 (e)
9.33 CNY
Jan 1, 2030 (e)
-7.06 CNY
Jan 1, 2031 (e)
0.00 CNY
The RemeGen Co EBIT per Share history
YEAREBIT per ShareYoY
est0.00CNY-100.00%
est-7.06CNY-175.66%
est9.33CNY+186.23%
est3.26CNY+91.14%
est1.70CNY+29.38%
1.32CNY-148.54%
-2.71CNY-2.34%
-2.78CNY+56.70%
-1.77CNY-628.78%
0.34CNY-123.22%
-1.44CNY+64.11%
-0.88CNY+98.20%
-0.44CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EBIT per Share of RemeGen Co is 1.32 CNY in 2025.

EBIT per Share of RemeGen Co changed from -2.71 CNY to 1.32 CNY, representing a -148.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — RemeGen Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — RemeGen Co